



- (51) **International Patent Classification:**
G01N 33/50 (2006.01) *G01N 33/574* (2006.01)
- (21) **International Application Number:**
PCT/US2024/036794
- (22) **International Filing Date:**
03 July 2024 (03.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/512,560 07 July 2023 (07.07.2023) US
- (71) **Applicant: DEWPOINT THERAPEUTICS, INC.**
[US/US]; 451 D Street, Suite 104, Boston, Massachusetts 02210 (US).
- (72) **Inventors: BOIJA, Ann;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **ISERMAN, Christiane;** c/o Dewpoint Therapeutics GmbH, Tatzberg 47, 01307 Dresden (DE). **ERKOSAN, Irem;** c/o Dewpoint Therapeutics GmbH, Tatzberg 47, 01307 Dresden (DE). **NENZ, Kathrin;** c/o Dewpoint Ther-

apeutics GmbH, Tatzberg 47, 01307 Dresden (DE). **BEUTEL, Oliver;** c/o Dewpoint Therapeutics GmbH, Tatzberg 47, 01307 Dresden (DE). **BAUMANN, Douglas G;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **SALAJIN, Konstantin;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US).

(74) **Agent: CHAPMAN, John D et al.;** Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) **Title:** B-CATENIN DEPOT DETECTION AND MODULATION ASSAYS




FIG. 3

(57) **Abstract:** The present application provides, in some aspects, methods of assaying for β -catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β -catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β -catenin associated disease), kits, and useful compounds identified therefrom.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*